Discontinuation report LIBTAYO
| Report ID | 212566 |
| Drug Identification Number | 02487152 |
| Brand name | LIBTAYO |
| Common or Proper name | Cemiplimab |
| Company Name | SANOFI-AVENTIS CANADA INC |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | CEMIPLIMAB |
| Strength(s) | 250MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 1 vial / carton |
| ATC code | L01XC |
| ATC description | |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2023-12-08 |
| Actual discontinuation date | 2023-12-08 |
| Remaining supply date | 2023-12-08 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Company contact information | email: CAINTERNET@sanofi.com Telephone: 1-800-265-7927 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v7 | 2023-12-09 | English | Compare |
| v6 | 2023-12-08 | French | Compare |
| v5 | 2023-12-08 | English | Compare |
| v4 | 2023-12-07 | French | Compare |
| v3 | 2023-12-07 | English | Compare |
| v2 | 2023-12-06 | French | Compare |
| v1 | 2023-12-06 | English | Compare |
Showing 1 to 7 of 7